Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) concerning whether the board has breached its fiduciary duties to shareholders.

On November 9, 2016, Alexion announced that it is investigating alleged improper sales practices related to its top drug, Soliris, which accounts for the majority of the Company's sales. The Company retained outside counsel and announced that it was delaying its third-quarter financial report. When this news was announced, Alexion shares fell in value.

If you own Alexion securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact J. Brandon Walker, Esq. by email at, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information, please go to

View source version on

Copyright Business Wire 2010